irinotecan has been researched along with mk-1775 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| Chang, W; Li, R; Liu, W; Shen, Q; Tao, K; Tao, R; Xie, G; Yin, Y; Zhang, P | 1 |
| Erickson, SW; Gorlick, R; Guo, Y; Houghton, PJ; Kolb, EA; Kurmasheva, RT; Maris, JM; Mosse, YP; Smith, MA; Teicher, BA | 1 |
| Cole, KA; Fox, E; Ijaz, H; Liu, X; Maris, JM; Minard, CG; Reid, JM; Santi, M; Surrey, LF; Voss, S; Weigel, BJ | 1 |
1 trial(s) available for irinotecan and mk-1775
| Article | Year |
|---|---|
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cerebellar Neoplasms; Child; Humans; Irinotecan; Medulloblastoma; Neuroblastoma; Protein-Tyrosine Kinases; Rhabdomyosarcoma | 2023 |
3 other study(ies) available for irinotecan and mk-1775
| Article | Year |
|---|---|
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Damage; Enzyme Inhibitors; Humans; Irinotecan; Mutation; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53 | 2018 |
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Female; Humans; Irinotecan; Kidney Neoplasms; Mice; Mice, SCID; Neoplasms, Experimental; Neuroblastoma; Pyrazoles; Pyrimidinones; Wilms Tumor; Xenograft Model Antitumor Assays | 2020 |